SCHEMBL16610911

SCHEMBL16610911

COc1nccc2c1c(-c1ccc(N3CCOCC3)cc1)nn2Cc1ccccc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.41
LRRK2 Q5S007 1/20 0.41
CETP P11597 1/20 0.41
CCNA2 P20248 2/20 0.40
CDK2 P24941 2/20 0.40
FYN P06241 1/20 0.40
CDK1 P06493 1/20 0.40
CDK4 P11802 1/20 0.40
CCNB1 P14635 1/20 0.40
CCND1 P24385 1/20 0.40
CDK7 P50613 1/20 0.40
CCNH P51946 1/20 0.40
KHK P50053 2/20 0.39
P2RX7 Q99572 1/20 0.39
GSK3B P49841 1/20 0.38
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
KDM4E B2RXH2 2/20 0.38
MAPT P10636 2/20 0.38
BRD4 O60885 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16610837 0.79 LRRK2 (0.44) TSHRLRRK2CCNA2CDK2FYN
SCHEMBL16610962 0.77 MAP4K1 (0.41) LRRK2CCNA2CDK2FYNCDK1
SCHEMBL16610876 0.74 SLC18A3 (0.41) TSHRLRRK2FYNGSK3BMEN1
SCHEMBL16610939 0.73 CNR1 (0.43) KDM4EADRA2AALDH1A1CYP1A2HSD17B10
SCHEMBL16611339 0.72 LRRK2 (0.39) TSHRLRRK2FYNGSK3BMEN1
SCHEMBL16611010 0.71 LRRK2 (0.38) TSHRLRRK2CCNA2CDK2FYN
SCHEMBL16611763 0.71 CCNA2 (0.43) LRRK2CCNA2CDK2CDK1CDK4
SCHEMBL16611322 0.70 TBK1 (0.43) LRRK2CCNA2CDK2CDK1CDK4
SCHEMBL16610949 0.70 LRRK2 (0.74) LRRK2
SCHEMBL13834157 0.69 JAK2 (0.47) LRRK2CCNA2CDK2FYNCDK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160251352-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICALS CO (JP) 2016-09-01 US disclosed
US-9371320-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-06-21 US disclosed
US-20150141406-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2015-05-21 US disclosed
EP-2857400-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2015-04-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160251352-A1 HETEROCYCLIC COMPOUND JAK2, JAK1, STAT3 TSHR 2755/4885LRRK2 1393/4885CETP 4855/4885
US-20150141406-A1 HETEROCYCLIC COMPOUND JAK2, JAK1, STAT3 TSHR 2755/4885LRRK2 1393/4885CETP 4855/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.